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improve motor fluctuations. The aim of this study is to assess the long- term safety and 
effectiveness	 of	 LCIG	 infusion	 in	 advanced	 Parkinson’s	 disease	 (PD)	 patients	 with	





life and caregiver burden for 1 year.
Results: There	was	a	high	number	of	AE,	but	manageable,	most	of	mild	and	moderate	
severity.	All	patients	experienced	significant	improvement	in	motor	fluctuations	with	
a reduction in mean daily off	time	of	4.87	hr	after	3	months	(n	=	37)	to	6.25	hr	after	
9	years	(n	=	2).	Diskynesias	remained	stables	in	28	patients	(75.7%)	and	improved	in	5	
patients	(13.5%).	There	was	no	neuropsychological	deterioration,	but	an	improvement	
in	 attentional	 functions,	 voluntary	motor	 control,	 and	 semantic	 fluency.	Quality	 of	
sleep	did	not	worsen,	and	there	was	an	 improvement	 in	the	subjective	parameters,	
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this	 stage	of	 the	disease,	 there	are	 three	 “second	 line”	device-	aided	
therapeutic options which may be offered to patients: deep brain 
stimulation	 (DBS),	 subcutaneous	 infusion	 of	 apomorphine	 (SIApo),	
and continuous intrajejunal infusion of levodopa- carbidopa intesti-
nal	gel	 (LCIG)	 (Martínez-	Martin	et	al.,	2015;	Munro	Neville,	Parsons,	
Askmark,	&	Nyholm,	2012).
Optimizing	 levodopa	 delivery	with	 LCIG	 infusion	 is	 a	 treatment	
option	for	advanced	PD	with	10	years	in	the	European	market.	LCIG	
infusion has demonstrated to improve motor fluctuations by reducing 
fluctuations	in	plasma	levodopa	levels.	The	effect	of	LCIG	in	other	set-
tings	has	been	poorly	studied.	Some	works	have	demonstrated	that	
treatment	with	 LCIG	may	 improve	nonmotor	 symptoms	of	PD,	may	
improve	 cognitive	 function	 and	 behavior	 (Sanchez-	Castañeda	 et	al.,	
2009;	Zibetti	 et	al.,	 2013),	quality	of	 sleep	 in	 these	patients	 (Eggert	
et	al.,	2008;	Honig	et	al.,	2009),	and	patient’s	quality	of	life	(QoL)	and	
caregiver	 burden	 (Isacson,	 Bingefors,	 Kristiansen,	 &	 Nyholm,	 2008;	
Puente	 et	al.,	 2010;	 Santos-	García	 et	al.,	 2012).	However,	 LCIG	 is	 a	
complex	 and	 expensive	 treatment	 and	 data	 on	 long-	term	 standard	
clinical practice therapy complications and their management are 
scarce.
There	 is	 still	 little	 known	about	 long-	term	 follow-	up	of	LGIC	 in-
fusion in PD patients. There are only two other 10- and 17- year 
retrospective	 studies	 (Nyholm,	 Johansson,	 Lennernäs,	 &	 Askmark,	
2012;	Nyholm	et	al.,	2008),	and	one	10-	year	prospective	study	(Lim,	
Schoeman,	&	Nguyen,	2015).	However,	the	10-	year	prospective	study	
only include follow- up of the percutaneous endoscopic gastrostomy 
(PEG)	procedure.
The	aim	of	this	study	is	to	analyze	our	long-	term	experience	in	the	
management	of	LCIG	treatment	 for	PD	with	motor	 fluctuations,	 the	
safety and effectiveness of this therapy in the control of motor fluc-
tuations,	and	its	effect	in	other	motor	and	nonmotor	symptoms,	such	
as	 cognitive	 and	 sleep	 disorders,	 impact	 in	 their	QoL	 and	 caregiver	
burden,	problems	found	and	actions	taken	to	solve	them,	and	reason	
for treatment discontinuation.
2  | MATERIALS AND METHODS
2.1 | Study design and patient selection
This	was	a	long-	term,	open-	label,	prospective,	observational	study	in	
37	patients	with	advanced	PD,	responders	to	levodopa,	and	with	disa-
bling	motor	 fluctuations.	All	patients	 included	 fulfilled	 the	UK	Brain	
Bank	criteria	(Hughes,	Daniel,	Kilford,	&	Lees,	1992)	for	the	diagnosis	
of	 idiopathic	 PD	 and	were	 experiencing	 severe	motor	 fluctuations,	
which	were	debilitating	in	daily	life,	despite	receiving	optimized	con-
ventional oral medications. Patients had been previously treated with 
oral	 levodopa	combined	with	entacapone,	rasagiline,	dopamine	ago-
nists,	 and/or	 apomorphine	 injections,	 9	 of	 them	 presented	 adverse	
events	(AEs)	with	SIApo	and	4	were	dismissed	for	DBS.	Patients	with	
atypical	 parkinsonian	 features	 were	 not	 included	 (Wenning	 et	al.,	
2000).
All	 PD	medication	was	 switched	 to	 LCIG	 (Duodopa®	AbbVie)	 at	
the	start	of	study	treatment.	LCIG	was	initially	administered	as	a	con-
tinuous duodenal infusion via a nasoduodenal probe using a portable 
external	pump	 in	order	 to	assess	 individual	 treatment	 response	and	
required	dose	during	a	test	period	of	3–10	days	 (4	days	 in	average).	
A	 gastroduodenal	 catheter	was	 then	 introduced	by	PEG	 for	 perma-
nent	infusion	of	perfused	LCIG.	Levodopa-	carbidopa	was	supplied	by	
the	 same	portable	pump	via	 a	 catheter	 into	 the	 jejunum,	with	dose	
delivery	individually	adjusted	to	minimize	Off time periods and dyski-
nesia during On	time	periods	(CADD-	Legacy® Duodopa®	PCA-	pump/
Smiths	Medical	ASD/St	Paul/MN/USA).
Three	 open-	label,	 prospective,	 observational	 substudies	 were	
carried out in three groups of patients from this population of pa-
tients	with	advanced	PD:	Nonmotor	assessment	of	cognition	and	be-
havior	(Substudy	1),	nonmotor	effects	on	quality	of	sleep	(Substudy	
2),	 and	 assessment	 of	 health	 status,	 QoL,	 and	 caregiver	 burden	
(Substudy	3).
The study was conducted in compliance with the ethical standards 
and	was	 approved	 by	 the	 Ethics	 Committee	 of	 the	 institution	 (Vall	
d’Hebron	University	Hospital),	and	followed	the	Spanish	Law	15/1999	
on Personal Character Data Protection concerning confidentiality of 
Patient’s	data.	All	patients	participating	in	the	study	signed	the	corre-







o	 AEs	 related	 to	PEG	procedures	and	gastrostomy,	 infusion	de-
vice,	and	treatment.
o	 Severity	of	AEs	evaluated	as	mild	 (event	well	 tolerated	by	pa-
tient,	causing	minimal	discomfort,	and	not	interfering	with	daily	
activities),	moderate	(the	event	causes	sufficient	discomfort	to	









o	 Motor	 fluctuations:	Off	 time	 in	 hours	 recorded	 in	 Parkinson’s	
Disease Diary©.
o Dyskinesia and other motor clinical aspects: evaluated with 
the	Unified	Parkinson’s	Disease	Rating	Scale	 (UPDRS)	part	 IV,	
UPDRS	 part	 II	 in	On and Off,	 UPDRS	 part	 III	 in	On and Off,	
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Hoehn	 and	Yahr	 (H&Y)	 stage	 in	On and Off,	 and	 Schwab	 and	
England	(S&E)	scale	in	On.




out in three subsets of this population are described below:





same environmental conditions and in patients in phase On. The cogni-
tive	examination	included:	tests	that	assessed	cognitive	areas	affected	
in	PD	according	to	the	literature,	psychometric	tests	with	well-	known	
parameters,	 tests	 that	can	be	used	 in	different	 types	of	populations	
(neurologic	and	psychiatric	disorders,	screening,	etc.),	and	tests	suit-
able for a population with low educational and cultural level.
•	 Attentional	 function:	 Forward	 Digit	 Span	 test	 of	Weschler	Adult	
Intelligence	Scale-Third	Edition	(WAIS-III);	Audio-verbal	attentional	
capacity;	and	Stroop	Color-Word	test.
•	 Executive	 functions:	 Backward	 Digit	 Span	 of	 WAIS-III;	 Audio-
verbal	working	memory;	 Stroop-word	 and	 Stroop-color	 subtests;	
F IGURE  1 Flow chart showing inclusion of patients along time
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Response	 inhibition	 capacity;	 Controlled	 Oral	 Word-Association	
Test	(FAS)	of	phonemic	verbal	fluency;	and	Category	Naming	Test	
(Animals)	of	semantic	verbal	fluency.
•	 Visual-constructional	 visuospatial	 and	 visuoperceptual	 functions:	
Clock Drawing Test—(order	 and	 copy)—visual-constructional; 
Reading clocks—simple	visuospatial	ability;	and	Luria	test	of	over-
lapping figures—visual perceptive skills function.
•	 Memory	and	learning:	Rey	Auditory-Verbal	Learning	Test	(RAVLT)—
Short-	and	long-term	audio-verbal	memory	and	recognition.





logical and behavioral symptoms.
Substudy 2—Quality of sleep:	Subgroup	of	patients	consecutively	in-
cluded	between	January	2009	and	June	2010,	evaluated	with	Epworth	
scale,	 fatigue	 scale,	 Pittsburg	 quality	 of	 sleep	 questionnaire,	 BDI,	 and	
Hamilton	anxiety	scale,	administered	prior	to	treatment	(at	baseline)	and	
6	months	 after	 treatment.	 In	 addition,	 an	 overnight	 polysomnography	
(PSG)	study	was	carried	out	at	these	timings.
Substudy 3—Health status, QoL, and caregiver burden:	Subgroup	of	
patients	consecutively	 included	between	June	2010	and	June	2011,	
evaluated	for	up	to	12	months,	with	the	Spanish	version	of	the	39-	item	





12 months after treatment.
2.3 | Statistical analysis
Statistical	 analysis	 was	 carried	 out	 using	 the	 SPSS	 statistical	 pack-



















On stage and 73.4 ± 21.8 in Off stage. Patients presented diskynesias 
from	1%	to	25%	of	 the	day	 in	14	patients	 (37.8%),	 from	26-	50%	 in	
19	patients	 (51.4%),	and	from	51%	to	75%	in	four	patients	 (10.8%);	
which	were	nondisabling	in	four	patients	(10.8%),	mildly	in	19	patients	
(51%),	 moderately	 in	 12	 patients	 (32.4%),	 and	 severely	 disabling	 in	
two	patients	(5.4%).	The	median	MMSE	score	was	28	(20–30).	There	





All	 patients	 received	 LCIG	 treatment	 for	 an	 average	 of	
43.6	±	31.5	months	 (1–120	months).	From	 the	37	patients	 receiving	
LCIG	 treatment,	 1	 (2,7%)	 arrived	 to	 10-	year	 control,	 2	 (5.4%)	 to	 9-	
year	control	(108	months),	13	(35.1%)	to	5-	year	control	(60	months),	













Although	 treatment	 was	 temporary	 discontinued	 as	 a	 conse-
quence	 of	 some	 of	 these	 AEs,	 they	 were	 manageable	 and	 actions	
taken	allowed	continuing	treatment	in	most	cases	(Table	1).	Treatment	
was	permanently	discontinued	in	14	patients	(37.8%):	seven	patients	
(18.9%)	who	 died	 due	 to	multiple	 comorbidity	with	 other	 diseases;	
three	 patients	 (8.1%)	 with	 disease	 progression	 with	 dementia	 and	









in daily mean Off	time	of	4.9	±	1.1	hr	after	3	months	(p <	.001)	in	37	
patients,	 4.9	±	1.1	 after	 2	years	 (p <	.001)	 in	 23	 patients,	 5.0	±	1.1	
     |  5 of 10DE FABREGUES Et Al.
TABLE  1 Adverse	events	(AEs)	and	actions	taken
AEs related with Type
Number (%) 
of patients Severity Action taken
PEG procedures 
Gastrostomy
Abdominal	pain,	nausea,	and	vomiting 12	(32.4%) Mild–Moderate Analgesic
Local	peritonitis	post-	PEG 5	(13.5%) Mild–Moderate Systemic	antibiotic
Pneumoperitoneum post- PEG 3	(8.1%) Moderate Diet
Granuloma 14	(37.8%) Mild Topical treatment
Stoma	dermatitis 12	(32.4%) 11	Moderate 
1	Serious
Topical treatment
Stoma	leakage 2	(5.4%) Moderate Topical treatment




Infusion device PEG replacement 34	(91.2%) Moderate Endoscopy and replacement
Connection breakage or failure 10	(27.0%) Mild Replacement
External	tube	breakage 2	(5.4%) Mild Replacement
PEG removal 4	(10.8%) Serious Maintaining	gastrostomy 
Endoscopy and repositioning or replacement
Exterior	output	of	intestinal	tube 11	(29.7%) Moderate Endoscopy and repositioning or replacement
Transitory obstruction of intestinal tube 13	(35.1%) Mild Tube	washing,	prokinetic	treatment
Permanent obstruction of intestinal tube 13	(35.1%) Moderate Tube	washing,	Endoscopy,	and	repositioning	
or replacement
Internal migration of intestinal tube 5	(13.5%) Moderate Endoscopy and repositioning or replacement
Migration	of	intestinal	tube	head	to	stomach 2	(5.4%) Moderate Prokinetic treatment 
Endoscopy and replacement
PEG hooked—foreign body reaction 3	(8.1%) Serious 2 Removal and new gastrostomy 
1	LCIG	withdrawal
Ulceration 2	(5.4%) Moderate Treatment with proton pump inhibitors
Pump malfunctioning 9	(24.3%) Moderate Replacement

















Confusion 11	(29.7%) 3	Mild 
2	Moderate
Dose adjustment




Impulsive and compulsive behavior 8	(21.6%) 5	Mild 
2	Moderate
Dose	adjustment,	neuroleptic	treatment




Vitamin	B12	deficit 12	(32.4%) NA Vitamin	supplement
Vitamin	B6	deficit 5	(13.5%) NA Vitamin	supplement
Homocysteine	excess 11	(29.7%) NA Vitamin	supplement
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after	5	years	 (p <	.001)	 in	13	patients,	and	6.3	±	0.4	after	9	years	 in	
two	patients	(p	=	.025).
Regarding	dyskinesia,	 none	of	 the	patients	 presented	 a	worsen-
ing	in	the	percentage	of	the	waking	time	with	dyskinesia,	which	was	
reduced	 in	6	patients	 (16.1%)	and	 remained	stable	 in	 the	 remaining	
31	 patients	 (83.8%).	 The	 changes	 in	 severity	 were	 not	 statistically	
significant	 (p	=	.176),	 severity	 of	 dyskinesias	 improved	 in	 5	 (13.5%),	
remained	stable	in	28	(75.7%),	and	worsened	in	4	(10.8%)	patients.
H&Y	motor	stages	significantly	improved	after	3	months	of	treat-





The	median	 S&E	 score	 of	 50	 pretreatment,	where	 patients	 had	
major	dependence	and	need	partial	help,	significantly	improved	to	80	
after	3	months	of	 treatment,	being	patients	 independent	 in	most	of	
the	daily	activities	(p <	.001).
Motor	symptoms	evaluated	with	UPDRS	part	 III	remained	stable	
with a slight improvement only significant for Off stage at midterm. 
The mean score in On stage changed from 22.2 ± 8.4 pretreatment to 
21.1	±	8.8	after	3	months	of	treatment	(p	=	.080),	and	the	mean	score	
in Off stage changed from 40.9 ± 13.2 pretreatment to 39.0 ± 12.0 
after	3	months	of	treatment	(p	=	.047).
Nonmotor	cognitive	function	and	behavior	evaluated	with	UPDRS	
part I improved from a mean score of 3.2 ± 2.4 pretreatment to 
2.5	±	1.7	 after	 3	months	 of	 treatment	 (p <	.001).	 However,	 no	 sig-




disorder	with	 compulsive	 and	 impulsive	behavior,	 pathological	 gam-
bling,	 compulsive	 buying,	 punding,	 and	 dopaminergic	 dysregulation	
syndrome)	persisted	but	did	not	worsen	 in	general	and	 impulse	and	
compulsive	behavior	improved,	without	any	new	case	of	this	compli-
cation during the follow- up.












3.5 | Substudy 2—Quality of sleep
This	substudy	 included	five	patients	 (one	male,	four	females)	with	a	
mean	age	of	69	 (60–76)	years	and	a	 time	of	evolution	of	PD	of	14	
















(6 months) p value




Boston	Naming	Test	30 21.8	±	6.1 22.4 ± 4.4 .854
WAIS-	III	Digits	Forward 6.4	±	2.5 6.8	±	1.6 .581
WAIS-	III	Digits	
Backward
3 ± 1.7 3.6	±	1.5 .276
RAVLT	A1 2.6	±	1.1 3.2 ± 0.8 .480
RAVLT	A2 3.8 ± 2.2 4.6	±	1.5 .180
RAVLT	A3 5.0 ± 1.7 5.4 ± 1.7 .705
RAVLT	A4 5.8 ± 2.5 7.2 ± 3.2 .465
RAVLT	A5 6.6	±	2.3 8.0 ± 3.7 .414
RAVLT	A7 3.2 ± 3.0 5.6	±	4.2 .066
Recognition	RAVLT 10.0	±	6.0 11.8	±	2.6 .854
Motor	sequences 14.6	±	8.4 19.4 ± 13.7 .276
Reciprocal coordination 16.6	±	11.7 17.2 ± 10.0 .715
The	clock	test–reading 12.6	±	3.9 12.8 ± 2.1 1.000
Luria	Test	of	
Overlapping Figures
13.2 ± 5.94 12.8 ± 1.3 1.000
Stroop-	word 58.6	±	25.7 69.5	±	38.9 1.000
Stroop-	color 45.2 ± 24.8 36.0	±	26.2 .461
Stroop-	word	color 18.5 ± 9.8 24.0	±	16.5 .465
Stroop-	word	color	
errors
0.7 ± 0.9 3.0	±	3.6 .357
The	clock	test–drawing 5.0 ± 2.1 4.2	±	2.6 .102
Results in mean ± standard deviation.
FAS,	Verbal	Fluency	Test	with	words	that	start	in	F-	A-	S;	WAIS,	Weschler	
Adult	 Intelligence	 Scale;	 RAVLT,	 Rey’s	 Auditory-	verbal	 learning	 test;	 
A1–A5,	Assay	1–5,	A7,	differed	audio-	verbal	memory.










The	 subjective	 questionnaire	 on	 somnolence	 showed	 that	 pa-
tients	 with	 somnolence	 improved	 after	 treatment,	 although	 not	








There	 was	 a	 significant	 global	 clinical	 improvement,	 improve-
ment	 of	QoL	 and	 health	 status,	 and	 lower	 healthcare	 burden	 after	
treatment	with	LCIG	 (Table	4).	There	was	a	 sustained	 improvement	
in	PD-	Q39	questionnaire	of	37%	at	3,	6,	and	12	months	with	a	mean	
decrease	of	21	points	(p <	.05).	EQ-	5D	questionnaire	significantly	im-








This is the first and longest follow- up prospective study carried out in 
Spain	on	long-	term	effects	of	LGIC	infusion	in	PD	patients.
Our	safety	profile	was	consistent	with	previous	studies	(Cáceres-	
Redondo	et	al.,	 2014;	Nyholm	et	al.,	 2008;	Zibetti	 et	al.,	 2014).	The	
most	frequent	issues	in	our	study	were	related	to	the	infusion	device	
and	mainly	of	mild	intensity,	although	we	also	found	serious	compli-
cations such as PEG removal in four patients and PEG hooked in three 
patients.	Most	of	these	complications	were	preventable	with	annual/
biennial PEG replacement. Complications related to PEG procedures 
and	gastrostomy	were	also	frequent	and	generally	mild,	although	there	






with	PNP,	 four	 cases	 already	 present	 prior	 to	 treatment,	 four	 cases	
of	small	fiber	PNP,	four	cases	of	axonal	subacute	PNP,	and	one	case	
of	serious	acute	axonal	PNP.	Almost	all	cases	evolved	to	stabilization	
or	 improvement	except	 the	 acute	PNP	case	who	was	 stabilized	but	
with	 neurologic	 sequelae.	 Presence	 of	 PNP	 was	 already	 described	
with	 long-	term	 treatment	 at	 high	 doses	 of	 oral	 levodopa	 (Puente	

















(6 months) p value
Objective parameters
Efficiency 66.2	±	9.3 55.2 ± 18.3 .225
Waking up during 
sleep
124.3 ± 82.0 100.8	±	60.9 .144
Sleep	latency 33.6	±	44.0 89.9 ± 112.1 .686
REM	latency 164.1	±	71.4 150.2 ± 78.4 .715
REM% 13.6	±	8.5 11.6	±	7.3 .144
N1% 18.0 ± 10.7 25.2	±	16.2 .686
N2% 54.3 ± 8.5 47.6	±	5.0 .043*
N3% 14.0 ± 8.4 15.7 ± 13.1 .686
Snoring	(n/h) 184 ± 275.2 285 ± 295.9 .109
AHI 3.0 ± 3.2 4.6	±	2.9 .593
Microawakenings 12.9	±	5.6 10.0 ± 3.2 .225
PLM 15.0 ± 11.0 10.8 ± 12.0 .345
Baseline	oximetry 94.4 ± 2.3 95.2 ± 2.1 .414
Mean	oximetry 93.6	±	2.4 94.2	±	2.6 .461
Minimum	oximetry 91.8 ± 2.5 89.0 ± 5.0 .194
CT90 0.6	±	1.3 0.6	±	0.6 .109
Subjective parameters
Epworth 5.6	±	3.6 2.8 ± 1.7 .131
Subjective	efficiency 66.7	±	24.3 70.6	±	23.2 .273
Pittsburg 10.2	±	6.9 8.4	±	6.0 .461






20.40	±	12.6 19.0 ± 13.7 .485
Results in mean ± standard deviation.
N,	 Sleep	 stages;	 AHI,	 Apnea	Hypopnea	 Index;	 PLM,	 periodic	 leg	move-
ment;	CT90,	oxygen	saturation	below	90%.
*p < .05 indicate significant differences compared to baseline.
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Despite	the	complexity	of	the	treatment	and	the	high	number	of	
AEs	occurred,	 as	most	AEs	were	manageable	 and	with	 the	 good	ef-





Several	 studies	 have	 shown	 the	 effectiveness	 of	 LCIG	 therapy	
in motor and nonmotor fluctuations in the standard clinical practice 
in	PD	(Buongiorno	et	al.,	2015;	Eggert	et	al.,	2008;	Fernandez	et	al.,	
2015).	In	our	study,	a	significant	reduction	in	mean	daily	Off time of 
4.8	hr	was	found	in	all	patients	after	LCIG	treatment,	which	is	slightly	
higher than the reduction in mean daily Off time of 4.4 hr found in 
a	12-	month	study	(Fernandez	et	al.,	2015),	and	of	4	hr	in	a	12-	week	
follow-	up	study	 (Olanow	et	al.,	2014).	Our	slightly	higher	results	are	
probably because the standard clinical practice allows greater agility 
and versatility in the treatment.
Improvement	of	dyskinesias	with	 long-	term	treatment	with	LCIG	
has been confirmed in several studies up to 7 years with significant 
reductions in On time during waking time without incapacitating dys-
kinesias	(Antonini	et	al.,	2013;	Santos-	García	et	al.,	2010),	and	global	




2009).	 In	our	 study	 the	percentage	of	waking	 time	with	dyskinesias	
was	reduced	 in	six	patients	and	maintained	 in	 the	remaining	31	pa-
tients,	and	severity	of	dyskinesias	improved	in	five	patients,	remaining	





Our study is not designed to compare the progressive motor deteri-
oration	of	natural	disease	evolution,	and	therefore	we	compare	with	
the	 same	population	 prior	 to	 treatment	 and	 at	midterm	 (3	months).	
Although	most	studies	report	a	global	improvement	in	daily	activities	
and	 motor	 complications	 subscales	 (Olanow	 et	al.,	 2014;	 Pålhagen	
et	al.,	 2012;	 Puente	 et	al.,	 2010;	 Slevin	 et	al.,	 2015),	 other	 stud-




In	 line	with	 precedent	 studies	 (Eggert	 et	al.,	 2008;	 Honig	 et	al.,	
2009)	 we	 also	 found	 significant	 improvement	 of	 nonmotor	 symp-
toms,	 particularly	 those	 concerning	 cognitive	 and	behavior	 function	
assessed	with	UPDRS	part	I.	The	Non-	Motor	Symptoms	Assessment	
Scale	for	Parkinson’s	disease	was	not	used	because	it	was	not	yet	val-
idated before the start of our prospective study.
In	 our	 experience,	 nonmotor	 neuropsychiatric	 disorders,	 which	
are	frequent	in	this	population,	persisted	with	treatment	but	did	not	
worsen in general. Impulse control disorders improved and there was 




with	 treatment	 at	midterm,	 as	 in	other	 studies	 (Fasano	et	al.,	 2012;	
Pickut,	van	der	Linden,	Dethy,	Van	De	Maele,	&	Zegers	de	Beyl,	2014).
Regarding	 the	 substudy	 of	 cognition	 and	 behavior	 assessment,	
after	LCIG	treatment,	patients	with	advanced	PD	had	no	impairment	
of	cognitive	function	and	there	were	some	improvements	in	attention,	























Baseline 1 week p value 3 months p value 6 months p value 1 year p value
PDQ-	39 56.9	±	11.4 41.9 ± 21.5 .097 35.7	±	18.6 .021* 35.5 ± 19.1 .021* 35.5 ± 18.8 .018*
EQ-	5D 9.3 ± 1.7 7.9	±	2.6 .041* 7.5 ± 2.1 .026* 8.2 ± 2.5 .140 7.5 ± 1.9 .042*
EQ-	VAS 54.9 ± 11.7 71.7	±	6.9 .017* 68.7	±	7.7 .027* 64.3	±	13.6 .249 66.2	±	9.9 .068
ZBI 30.9 ± 17.7 26.0	±	17.8 .173 22.2 ± 10.8 .042* 27.5	±	16.2 .074 27.7 ± 15.5 .058
Results in mean ± standard deviation.
PDQ-	39,	quality-	of-	life	questionnaire	in	PD—39	items;	EQ-	5D,	European	Quality	of	life—5	dimensions;	EQ-	VAS,	European	quality-	of-	life	Visual	Analogue	
Scale;	ZBI,	Zarit	Burden	Index.
*p < .05 indicate significant differences compared to baseline.
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such	 as	 PD,	 have	 a	 considerable	 social	 burden,	 particularly	 for	 the	
caregiver.	 In	 our	 study	 LCIG	 treatment	 reduced	 in	 a	 20%	 the	 care-
giver	burden	at	midterm	(3	months)	and	a	10%	at	long	term	(1	year).	
Although	the	statistical	potency	was	low	due	to	the	small	sample	size,	
there	 were	 no	 evidences	 that	 patients	 undergoing	 this	 treatment,	
despite	 the	 limitations	 and	 complications,	 had	worse	QoL	 or	worse	
caregiver burden. Results from other studies found a tendency toward 
an	 improvement	 in	 caregiver	burden	with	 LCIG	 treatment	 (Cáceres-	
Redondo	et	al.,	2014;	Fasano	et	al.,	2012;	Olanow	et	al.,	2014;	Sensi	
et	al.,	2014;	Slevin	et	al.,	2015).
The safety and effectiveness results are particularly important due 
to	the	long-	term	prospective	follow-	up,	leading	to	a	better	knowledge	
of	LCIG	therapy	in	all	aspects,	both	motor	and	nonmotor,	and	on	its	
complications. This is the major strength of this study. The study pro-
vides valuable information obtained in the standard clinical practice 
conditions,	and	will	help	to	optimize	treatment	for	patients	currently	




LCIG	 may	 be	 considered	 a	 complex	 treatment	 strategy	 for	 ad-
vanced PD with motor fluctuations where drug combinations currently 
available did not provide satisfactory results. Considering the high cost 
of	LCIG	treatment,	the	potential	serious	AEs,	and	their	complexity,	the	
most likely candidates for this treatment should be identified and a 
multidisciplinary	specialized	and	protocolized	management	is	recom-




and for improvement or nonworsening of other motor and nonmotor 
aspects	of	PD,	being	well	tolerated	and	safe,	long-	term	sustained,	and	
feasible for use in the standard clinical practice.
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